The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R06 | Antihistamines for systemic use | |
| 3 | R06A | Antihistamines for systemic use | |
| 4 | R06AX | Other antihistamines for systemic use | |
| 5 | R06AX28 | Rupatadine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Rupatadine |
Rupatadine is a second-generation antihistamine, long-acting histamine antagonist, with selective peripheral H1-receptor antagonist activity. Some of the metabolites (desloratadine and its hydroxylated metabolites) retain an antihistaminic activity and may partially contribute to the overall efficacy of the drug. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| RAZTROL Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| RINIALER Oral solution | Medicines Authority (MT) | MPI, EU: SmPC | |
| RINIALER Tablet | Medicines Authority (MT) | MPI, EU: SmPC | |
| RUPAFIN Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
